ArticleThe Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale2026
Nonantibiotic Treatment of Clinical Multidrug-Resistant Bacterial Isolates Using Chitosan Nanoparticles as a Carrier for the Supernatant of Mesenchymal Stem Cells.
Article in The Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Nonantibiotic Treatment of Clinical Multidrug-Resistant Bacterial Isolates Using Chitosan Nanoparticles as a Carrier for the Supernatant of Mesenchymal Stem Cells.The Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study aimed to evaluate the antimicrobial potential of the supernatant (conditioned medium) of mesenchymal stem cells-derived conditioned medium (MSCs CM), incorporated in chitosan nanoparticles (CS NPs), against multidrug-resistant (MDR) clinical isolates. Dynamic light scattering (DLS), zeta potential (ZP), and scanning electron microscopy (SEM) assays were used to characterize CS NPs. MSCs CM was incorporated into CS NPs, and its release pattern from the composite (MSCs CM-CS NPs) was evaluated. Antibacterial properties of MSCs CM-CS NPs, as well as MSCs CM and CS NPs, were assessed by the microbroth dilution technique. The average particle size of most CS NPs was 85.2 nm, and their zeta potential was 32.1 mV. SEM findings supported the morphology of the prepared CS NPs and the synthesized composite (MSCs CM-CS NPs). Entrapment efficiency of the new construct was 71%. The antimicrobial activity of the new construct (MSCs CM-CS NPs: 1000 μg/mL + 0.05%) against MDR bacteria was significantly higher compared with MSCs CM (1000 μg/mL) and CS NPs (0.05%) each alone. This composite exhibited the synergistic antibacterial activity of the combination of MSCs CM and CS NPs, resulting in a more potent dose-dependent antibacterial activity against MDR clinical isolates.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.